{"title":"Correction to Lancet Neurol 2024; 23: 1205–13","authors":"","doi":"10.1016/s1474-4422(24)00495-2","DOIUrl":null,"url":null,"abstract":"<em>Sheth KN, Albers GW, Saver JL, et al. Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.</em> Lancet Neurol <em>2024; <strong>23:</strong> 1205–13</em> —In this Article, the CHARM Trial investigators and the appendix have been updated. This correction has been made as of Dec 18, 2024.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"54 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1474-4422(24)00495-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sheth KN, Albers GW, Saver JL, et al. Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Neurol 2024; 23: 1205–13 —In this Article, the CHARM Trial investigators and the appendix have been updated. This correction has been made as of Dec 18, 2024.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
